AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15255164
Drug: irinotecan combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan combined with a platinum agent
Trial: 12587182
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline (2.5%) infusion
Trial: 12587182
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (0.9%) infusion
Trial: 9577356
Drug: Subcutaneous octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous octreotide 250 micrograms twice daily
Trial: 3285637
Drug: Vitamin D2
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin D2 supplementation (400 IU, 5-7 times weekly)
Trial: 30355512
Drug: Daily TPTD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily TPTD for 24 months (Rx-Naïve)
Trial: 30355512
Drug: Daily TPTD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily TPTD for 24 months (ALN-Rx)
Trial: 28980452
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of furosemide (initial dose 80 mg/day, can be doubled if poor response)
Trial: 28980452
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of furosemide (twice-daily bolus injection)
Trial: 28980452
Drug: High diuretic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High diuretic dose (furosemide >120 mg/day)
Trial: 28980452
Drug: Low diuretic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low diuretic dose (furosemide ≤120 mg/day)
Trial: 19847131
Drug: Constraint-induced movement
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-induced movement therapy combined with an intensive rehabilitation program
Trial: 11905959
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (600 mg alpha‐tocopherol, 1000 mg ascorbic acid, 32 mg beta‐carotene)
Trial: 7944656
Drug: Adjuvant total
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant total parenteral nutrition
Trial: 7944656
Drug: No adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjuvant total parenteral nutrition (Control)
Trial: 2904825
Drug: Bisoprolol (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (10‐20 mg)
Trial: 2904825
Drug: Atenolol (50‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (50‐100 mg)
Trial: 27575791
Drug: Treatment retention
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment retention
Trial: 16379563
Drug: Flax fiber
RxNorm normalized name: Flax fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flax fiber supplement (15 g/day)
Trial: 16379563
Drug: Psyllium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium supplement (10.4 g/day)
Trial: 10561205
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with tamoxifen
Trial: 10561205
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without tamoxifen
Trial: 10561205
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with or without tamoxifen
Trial: 3889258
Drug: Furosemide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (1 mg/kg/12 hr intravenously or 2 mg/kg/12 hr orally)
Trial: 30372830
Drug: MgSO4 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgSO4 (50 mg/kg infused intravenously within 15 min)
Trial: 19703327
Drug: DHA (220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (220 mg/d)
Trial: 19703327
Drug: DHA+AA (220
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA+AA (220 mg each/d)
Trial: 12377399
Drug: Theophylline (0.66
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (0.66 mg/kg, maximum dose of 500 mg)
Trial: 12377399
Drug: Schizophrenia group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schizophrenia group (baseline results from 17 drug-treated patients)
Trial: 10463785
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose (1 ml 30% glucose) prior to skin puncture
Trial: 10463785
Drug: Heel stick
RxNorm normalized name: Zit Stick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heel stick without oral glucose
Trial: 10463785
Drug: Venepuncture without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Venepuncture without oral glucose
Trial: 2688080
Drug: Tenoxicam suppositories
RxNorm normalized name: tenoxicam Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam suppositories (20 mg once daily)
Trial: 2688080
Drug: Piroxicam suppositories
RxNorm normalized name: piroxicam Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam suppositories (20 mg once daily)
Trial: 31926605
Drug: Intravenous siponimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous siponimod (0.25 mg/3 h)
Trial: 31926605
Drug: Intravenous siponimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous siponimod (1 mg/24 h)
Trial: 31926605
Drug: Oral siponimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral siponimod (0.25 mg)
Trial: 31926605
Drug: Intravenous siponimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous siponimod (0.25 mg/3 h) and Oral siponimod (0.25 mg)
Trial: 11130251
Drug: IV granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV granisetron (G) 3 mg once a day
Trial: 11130251
Drug: IV tropisetron
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV tropisetron (T) 5 mg once a day
Trial: 11130251
Drug: IV ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV ondansetron (O) 8 mg twice daily
Trial: 11130251
Drug: IV granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV granisetron (G)
Trial: 8227493
Drug: Fluvoxamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine treatment in OCD patients with chronic tic disorder
Trial: 8227493
Drug: Fluvoxamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine treatment in OCD patients without chronic tic disorder
Trial: 30280640
Drug: Transcatheter mitral-valve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcatheter mitral-valve repair plus medical therapy (device group)
Trial: 24729507
Drug: Azithromycin 1
RxNorm normalized name: azithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 1 g
Trial: 7580297
Drug: Solvent solution
RxNorm normalized name: solvent yellow 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solvent solution
Trial: 1935285
Drug: Metered dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered dose inhaler (MDI) via spacer (InspirEase)
Trial: 28494906
Drug: Morphine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine group (GM): 20ml 0.5% bupivacaine + 10mg morphine sulphate diluted in 20ml saline
Trial: 28494906
Drug: Morphine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine group (GM)
Trial: 26920896
Drug: Zedoary herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zedoary herbal tea (ZHT) T1 (500 mg ZRDP)
Trial: 26920896
Drug: Zedoary herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zedoary herbal tea (ZHT) T2 (1 g ZRDP)
Trial: 26920896
Drug: Zedoary herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zedoary herbal tea (ZHT) T3 (1.5 g ZRDP)
Trial: 7699642
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) 1.5 g/kg every 2 weeks for 2 months, then monthly for 4 months (total: up to 9 infusions over 6 months)
Trial: 3322590
Drug: Mitoxantrone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone (10 mg/m2) with cyclophosphamide (500 mg/m2) and 5-fluorouracil (500 mg/m2)
Trial: 3322590
Drug: Doxorubicin (50-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (50-60 mg) with cyclophosphamide (500 mg/m2) and 5-fluorouracil (500 mg/m2)
Trial: 27555133
Drug: Intravenous 1g
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 1g paracetamol (Group P)
Trial: 27555133
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution (Group C)
Trial: 12611908
Drug: 15 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg/day ursodeoxycholic acid (UDCA) for 20 days
Trial: 12611908
Drug: No bile
RxNorm normalized name: bile salts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bile acid supplement (control)
Trial: 10575906
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E combined with potent inhibitors of platelet aggregation
Trial: 11144988
Drug: Rofecoxib (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (75 mg once daily)
Trial: 2654206
Drug: MEFAE sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEFAE sodium 720 mg daily
Trial: 2654206
Drug: DMFAE 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMFAE 240 mg daily
Trial: 2654206
Drug: MEFAE sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEFAE sodium up to 240 mg daily
Trial: 968056
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg 15(S)‐15 methyl PGF2alpha in viscous medium (Tylose)
Trial: 968056
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg 15(S)‐15 methyl PGF2alpha in viscous medium (Hyskon)
Trial: 968056
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg 15(S)‐15 methyl PGF2alpha in non‐viscous medium repeated at 12 hours
Trial: 968056
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg 15(S)‐15 methyl PGF2alpha in viscous medium
Trial: 29058097
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (cisplatin 80 mg/m2 for six cycles plus capecitabine 1000 mg/m2 orally bid days 1-14 or 5-fluorouracil 800 mg/m2/day continuous IV infusion days 1-5 every 3 weeks)
Trial: 24598306
Drug: Methylprednisolone (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (two intravenous doses of 250 mg each)
Trial: 17985809
Drug: Mindful Awareness
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mindful Awareness in Body-oriented Therapy (MABT)
Trial: 17150108
Drug: Valproic acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid (VPA), mean dose of 850 mg/d for 18 months (range 6-27 months)
Trial: 14695410
Drug: Placebo (660
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (660 ml beverage with artificial sweeteners)
Trial: 1796197
Drug: morniflumate combined
RxNorm normalized name: morniflumate
DrugBank: Morniflumate (DB09285)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morniflumate combined with amoxicillin
Trial: 1796197
Drug: imidazole-2-hydroxybenzoate combined
RxNorm normalized name: imidazole-2-hydroxybenzoate
DrugBank: Imidazole salicylate (DB13860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: imidazole-2-hydroxybenzoate combined with amoxicillin
Trial: 1796197
Drug: antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antibiotic therapy alone
Trial: 6666232
Drug: ISDN (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISDN (3 mg intracoronary)
Trial: 6666232
Drug: ASA (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA (1.0 g intravenous and 100 mg intracoronary)
Trial: 6666232
Drug: ASA (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA (before ISDN administration)
Trial: 28866447
Drug: Verum tDCS
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum tDCS (2-mA, twice-daily sessions for 5-days)
Trial: 22563194
Drug: LCR35 (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCR35 (n = 25) at a minimum daily dose of 6 × 10(8) colony forming units for 4 weeks
Trial: 17661765
Drug: Oral chili
RxNorm normalized name: Chili oleoresin
DrugBank: Capsicum oleoresin (DB11131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chili (5 g daily x 3 days)
Trial: 17661765
Drug: Oral chili
RxNorm normalized name: Chili oleoresin
DrugBank: Capsicum oleoresin (DB11131)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chili with 1-mg intravenous granisetron
Trial: 17661765
Drug: Intravenous granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous granisetron after placebo ingestion
Trial: 16310024
Drug: Psychological stressor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological stressor (administered to 21 patients during the last 90 min of 24-h oesophageal pH monitoring)
Trial: 16310024
Drug: No-stress control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-stress control condition (administered to the remaining participants)
Trial: 10203878
Drug: 25% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% of the 4-hourly opioid dose
Trial: 10203878
Drug: 50% of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% of the 4-hourly opioid dose
Trial: 7780069
Drug: Meperidine, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine, 25 to 75 mg (n = 10)
Trial: 7780069
Drug: Vecuronium, 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium, 0.1 microgram/kg (n = 10), continued as an infusion at 1.0 microgram/kg/min for 4 hours
Trial: 393465
Drug: Protacine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protacine (150 mg, 3 times daily for 21 days)
Trial: 393465
Drug: Indomethacin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (50 mg, 3 times daily for 21 days)
Trial: 30649375
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose (twice the maintenance dose)
Trial: 14979213
Drug: Keyouling oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keyouling oral liquid (high-dosage group)
Trial: 14979213
Drug: Keyouling oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Keyouling oral liquid (treatment group)
Trial: 11305831
Drug: 0.15 mg
RxNorm normalized name: iodine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg clonidine (Group-CL, n=20)
Trial: 11305831
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg diazepam (Group-DZ, n=20)
Trial: 9220179
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (2 micrograms/kg/min)
Trial: 9220179
Drug: Intravenous bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous bumetanide (1 mg b.i.d.) alone
Trial: 11767421
Drug: Netilmicin 2
RxNorm normalized name: netilmicin 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netilmicin 2 mg kg‐1
Trial: 11767421
Drug: Cefuroxime 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 20 mg kg‐1
Trial: 11767421
Drug: Metronidazole 7.5
RxNorm normalized name: metronidazole 7.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 7.5 mg kg‐1
Trial: 11767421
Drug: Cefuroxime 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 20 mg kg‐1 and Metronidazole 7.5 mg kg‐1
Trial: 29570588
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of parenteral nutrition
Trial: 25768376
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg/kg for intubation followed by sugammadex 4.0 mg/kg for reversal.
Trial: 25768376
Drug: Succinylcholine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1.0 mg/kg for intubation with spontaneous recovery.
Trial: 22672501
Drug: vildagliptin/metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vildagliptin/metformin
Trial: 22672501
Drug: metformin only
RxNorm normalized name: Metformin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metformin only
Trial: 17121765
Drug: Bromelain 800
RxNorm normalized name: Bromelain
DrugBank: Bromelains (DB13281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromelain 800 mg/day
Trial: 12933427
Drug: Remifentanil 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 0.75 micro g/kg in bolus, followed by continuous infusion of 0.075 micro g x kg(‐1) x min(‐1) (Group L)
Trial: 12933427
Drug: Remifentanil 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil 1.5 micro g/kg in bolus, followed by continuous infusion of 0.15 micro g x kg(‐1) x min(‐1) (Group H)
Trial: 11529283
Drug: Formoterol (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (twice daily 24 microg by Turbuhaler)
Trial: 11529283
Drug: Salmeterol (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (twice daily 100 microg by Diskhaler)
Trial: 8220396
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid (protein) capsules
Trial: 8220396
Drug: Lactose (placebo)
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose (placebo) capsules
Trial: 3327931
Drug: Hydrochlorothiazide (HCTZ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ, 12.5 mg twice daily)
Trial: 31389672
Drug: 0.02% PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02% PCA lotion for 8 weeks
Trial: 30606315
Drug: Universal isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Universal isoniazid preventive therapy (IPT)
Trial: 25680623
Drug: 4-drug regimen
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4-drug regimen (irinotecan, oxaliplatin, tegafur-uracil with leucovorin and cetuximab)
Trial: 18510819
Drug: Taste-masked quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taste-masked quinine sulphate pellets (600 mg single dose for adults; 10-12.5 mg/kg every 8 hours for 7 days for children)
Trial: 18510819
Drug: Commercially available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available tablets (control for adults)
Trial: 16918261
Drug: Epratuzumab (humanised
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epratuzumab (humanised anti-CD22 antibody)
Trial: 8922570
Drug: Erythromycin estolate
RxNorm normalized name: Erythromycin Estolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin estolate (40 mg/kg/d in two divided doses for five days)
Trial: 8922570
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V (30 mg/kg/d in three divided doses for ten days)
Trial: 29390048
Drug: Intermediate-dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose cytarabine (1000 mg/m2 twice daily on days 1, 3, 5, 7) plus mitoxantrone (10 mg/m2 days 1-3) (IMA)
Trial: 29390048
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction therapy with cytarabine (100 mg/m2 continuously days 1-7) plus daunorubicin (45 mg/m2 days 3-5) (DA)
Trial: 29390048
Drug: Intermediate-dose cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose cytarabine plus mitoxantrone (IMA)
Trial: 29390048
Drug: Standard induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard induction therapy with cytarabine plus daunorubicin (DA)
Trial: 28453759
Drug: Leukapheresis treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leukapheresis treatment with CCL25 column
Trial: 26222774
Drug: eGFR <60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR <60 ml/min/1.73 m2 and elevated OPG
Trial: 26222774
Drug: eGFR ≥60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR ≥60 ml/min/1.73 m2 and low OPG
Trial: 16507398
Drug: exemestane 25
RxNorm normalized name: exemestane 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: exemestane 25 mg daily and celecoxib 400 mg twice-daily (Group A)